Cathie Wood is a leading advocate of innovative technologies. Her latest investment, Tempus AI Inc., (NASDAQ: TEM), represents a bet made on artificial intelligence.
Wood, who is known for her focus on transformational technologies and her investment in Tempus, reflects her belief in the potential of the AI-based health tech sector.
Since its debut on Nasdaq in June, Tempus shares have risen by over 50%, indicating growing investor interest.
Wood allocates $1.5 Million to Tempus AI
Wood recently invested over $1,5 million in Tempus AI via two of her flagship funds.
Wood made this investment at a moment when Tempus’ shares traded at a discount of 15% compared with their July peak, indicating that Wood has already seen significant returns on his investments.
AI-driven healthcare company, Health-Tech, is specialized in developing precision medicine tailored for individual patients. It addresses conditions like depression, heart issues and oncological problems.
Wall Street analysts have given Tempus a “buy” consensus rating, indicating their confidence in the company’s growth.
Tempus, despite its impressive technology and a substantial revenue last year of more than $530 millions dollars, is still not profitable.
Wood’s investment strategy included replacing Teladoc Health with Tempus in her portfolio due to Teladoc’s recent underperformance on the financial front and its withdrawal of full-year guidance.
Why should you invest in Natera?
Wood also showed interest in Natera Inc., a health-tech firm (NASDAQ: NTRA).
Natera has its own risks, even though its stock price nearly doubled in the past year and recent earnings have exceeded expectations by 50 percent.
A lawsuit has been filed against the clinical genetics testing company for unfair billing practices.
The Department of Justice settled a similar case in 2018 for an amount of $11 million.
Natera is a risky investment because of the ongoing legal issues.
Even though not all lawsuits have negative results for the company, they may impact stock performance and investor confidence.
Investors are advised to be cautious when investing in firms that face significant legal issues.
Is Tempus Ai a safe bet?
Cathie Woods’ substantial investment in Tempus AI demonstrates her confidence in the ability of the company to capitalise on the increasing demand for AI driven health solutions.
Tempus is a potential lucrative investment in the sector of health tech, thanks to its strong track record and innovative approach.
Investors should be aware of the potential risks involved with certain investments. For example, Natera has strong financials but faces legal obstacles that may affect its performance in the future.
Wood is navigating the ever-changing technology landscape. Tempus AI, however, stands out in the AI healthcare field as a major player.
It remains to be determined whether it can maintain this upward trajectory, and deliver its promises. However, Wood’s investment is a vote of confidence for the potential of the company.
Cathie wood bets on Tempus AI, is it the future of health tech? This post may change as new information becomes available
This site is for entertainment only. Click here to read more
